CAPTRUST Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.1M | Sell |
36,774
-12,713
| -26% | -$696K | ﹤0.01% | 1273 |
|
|
2026
Q1 | $2.8M | Buy |
49,487
+10,460
| +27% | +$610K | ﹤0.01% | 1039 |
|
|
2025
Q4 | $2.32M | Sell |
39,027
-8,434
| -18% | -$459K | ﹤0.01% | 1028 |
|
|
2025
Q3 | $2.57M | Buy |
47,461
+8,059
| +20% | +$461K | 0.01% | 908 |
|
|
2025
Q2 | $2.17M | Buy |
39,402
+16,817
| +74% | +$990K | ﹤0.01% | 935 |
|
|
2025
Q1 | $1.6M | Buy |
22,585
+8,278
| +58% | +$557K | ﹤0.01% | 1012 |
|
|
2024
Q4 | $940K | Buy |
14,307
+3,407
| +31% | +$228K | ﹤0.01% | 1267 |
|
|
2024
Q3 | $766K | Buy |
10,900
+2,770
| +34% | +$232K | ﹤0.01% | 1341 |
|
|
2024
Q2 | $669K | Buy |
8,130
+2,278
| +39% | +$190K | ﹤0.01% | 1367 |
|
|
2024
Q1 | $511K | Sell |
5,852
-1,475
| -20% | -$132K | ﹤0.01% | 1472 |
|
|
2023
Q4 | $706K | Sell |
7,327
-303
| -4% | -$26.8K | ﹤0.01% | 1489 |
|
|
2023
Q3 | $675K | Buy |
7,630
+1,953
| +34% | +$174K | ﹤0.01% | 1441 |
|
|
2023
Q2 | $492K | Buy |
5,677
+896
| +19% | +$84.3K | ﹤0.01% | 1641 |
|
|
2023
Q1 | $465K | Buy |
4,781
+1,420
| +42% | +$147K | ﹤0.01% | 1449 |
|
|
2022
Q4 | $348K | Buy |
3,361
+235
| +8% | +$22.1K | ﹤0.01% | 1551 |
|
|
2022
Q3 | $265K | Buy |
3,126
+22
| +0.7% | +$1.96K | ﹤0.01% | 1630 |
|
|
2022
Q2 | $257K | Sell |
3,104
-170
| -5% | -$13.5K | ﹤0.01% | 1520 |
|
|
2022
Q1 | $252K | Sell |
3,274
-462
| -12% | -$38.7K | ﹤0.01% | 1556 |
|
|
2021
Q4 | $330K | Buy |
3,736
+263
| +8% | +$21.7K | ﹤0.01% | 1333 |
|
|
2021
Q3 | $268K | Sell |
3,473
-209
| -6% | -$16.5K | ﹤0.01% | 1360 |
|
|
2021
Q2 | $307K | Buy |
3,682
+300
| +9% | +$23.8K | ﹤0.01% | 1257 |
|
|
2021
Q1 | $255K | Buy |
3,382
+73
| +2% | +$5.96K | ﹤0.01% | 1316 |
|
|
2020
Q4 | $290K | Sell |
3,309
-421
| -11% | -$33.4K | ﹤0.01% | 1045 |
|
|
2020
Q3 | $283K | Sell |
3,730
-567
| -13% | -$57.4K | ﹤0.01% | 901 |
|
|
2020
Q2 | $541K | Sell |
4,297
-207
| -5% | -$20.6K | 0.01% | 681 |
|
|
2020
Q1 | $376K | Buy |
4,504
+236
| +6% | +$20.3K | 0.01% | 658 |
|
|
2019
Q4 | $359K | Buy |
4,268
+1,283
| +43% | +$96.9K | 0.01% | 788 |
|
|
2019
Q3 | $201K | Hold |
2,985
| – | – | 0.01% | 570 |
|
|
2019
Q2 | $256K | Sell |
2,985
-221
| -7% | -$18.9K | 0.01% | 514 |
|
|
2019
Q1 | $285K | Sell |
3,206
-302
| -9% | -$28K | 0.01% | 453 |
|
|
2018
Q4 | $299K | Buy |
3,508
+248
| +8% | +$23.6K | 0.02% | 368 |
|
|
2018
Q3 | $316K | Buy |
+3,260
| New | +$325K | 0.01% | 361 |
|
Other funds holding BMRN
VPC
CAPTRUST Financial Advisors's BMRN Position: Q2 2026 in Review
CAPTRUST Financial Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 26% in Q2 2026, selling an estimated $696K and leaving 36,774 shares worth $2.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1273.
CAPTRUST Financial Advisors first reported a position in BMRN in Q3 2018 and has held it in 32 quarters since. The position peaked at $2.8M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- CAPTRUST Financial Advisors held 36,774 shares of BioMarin Pharmaceuticals worth $2.1M as of Q2 2026.
- CAPTRUST Financial Advisors sold 12,713 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $696K.
- BioMarin Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #1273 holding.
- CAPTRUST Financial Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- CAPTRUST Financial Advisors's BioMarin Pharmaceuticals position peaked at $2.8M in Q1 2026.
- 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.